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39 end formation of pre-mRNA and
phosphorylation of Ser2 on the RNA
polymerase II CTD are reciprocally
coupled in human cells
Lee Davidson, Lisa Muniz, and Steven West1
Wellcome Trust Centre for Cell Biology, Edinburgh EH9 3JR, United Kingdom
39 end formation of pre-mRNAs is coupled to their transcription via the C-terminal domain (CTD) of RNA
polymerase II (Pol II). Nearly all protein-coding transcripts are matured by cleavage and polyadenylation (CPA),
which is frequently misregulated in disease. Understanding how transcription is coordinated with CPA in human
cells is therefore very important. We found that the CTD is heavily phosphorylated on Ser2 (Ser2p) at poly(A) (pA)
signals coincident with recruitment of the CstF77 CPA factor. Depletion of the Ser2 kinase Cdk12 impairs Ser2p,
CstF77 recruitment, and CPA, strongly suggesting that the processes are linked, as they are in budding yeast.
Importantly, we additionally show that the high Ser2p signals at the 39 end depend on pA signal function.
Down-regulation of CPA results in the loss of a 39 Ser2p peak, whereas a new peak is formed when CPA is induced
de novo. Finally, high Ser2p signals are generated by Pol II pausing, which is a well-known feature of pA site
recognition. Thus, a reciprocal relationship between early steps in pA site processing and Ser2p ensures efficient 39
end formation.
[Keywords: RNA polymerase II; C-terminal domain; cleavage and polyadenylation; pausing; Ser2; Cdk12]
Supplemental material is available for this article.
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Most eukaryotic pre-mRNAs are matured at their 39 end
by cleavage and polyadenylation (CPA) (Proudfoot 2012).
During CPA, several multiprotein complexes (CPSF,
CstF, CFI, and CFII) assemble onto the poly(A) (pA) signal
within the pre-mRNA, with many additional factors also
implicated (Zhao et al. 1999; Shi et al. 2009). A pA signal
usually consists of an AAUAAA hexamer followed by
a U-rich or G/U-rich element, although variants of the
hexamer motif are also functional (Tian andGraber 2012).
Pre-mRNA cleavage occurs between these two elements
and is performed by CPSF73 (Mandel et al. 2006). Fol-
lowing cleavage, the upstream product is polyadenylated,
and the 39 product is degraded (Kim et al. 2004; Gromak
et al. 2006). The only pre-mRNA transcripts not poly-
adenylated are those that code for replication-dependent
histones. However, these transcripts usemany of the same
factors for cleavage of their 39 ends, including CPSF73 as
the endonuclease (Dominski et al. 2005; Kolev and Steitz
2005).
CPA is closely coupled to transcription via the C-terminal
domain (CTD) of RNA polymerase II (Pol II), which is
composed of repeats of the Tyr–Ser–Pro–Thr–Ser–Pro–Ser
heptapeptide (McCracken et al. 1997). A dynamic binding
platform for RNA biogenesis factors is created by cis/
trans isomerization of prolines and phosphorylation of
the other amino acids (Buratowski 2009; Eick and Geyer
2013). Of these modifications, Ser2 phosphorylation
(Ser2p) is most strongly linked to 39 end formation. In
budding yeast, the Ser2 kinase Ctk1 is required for the
cotranscriptional recruitment of several 39 end processing
factors to Pol II (Ahn et al. 2004). In humans, Cdk9, Brd4,
and Cdk12 can phosphorylate CTD on Ser2, but Cdk12 is
the proposed ortholog of Ctk1 (Peterlin and Price 2006;
Bartkowiak et al. 2010; Devaiah et al. 2012). Similar to
Ctk1, Cdk12 does not generally affect transcription, al-
though a subset of genes is regulated (Blazek et al. 2011).
Whether Cdk12 performs a function analogous to Ctk1 in
coordinating 39 end formation and transcription has not
been tested. CTD phosphorylation status is also influ-
enced by phosphatases, of which Fcp1 acts on Ser2p (Cho
et al. 2001).
Although the importance of Ser2p for 39 end processing
is well established in yeast, the relationship between
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these two events is less well understood in mammals.
However, Pol II lacking in Ser2 does not support efficient
CPA in human cells (Gu et al. 2012). Moreover, Pol II that
is most heavily phosphorylated on Ser2 often occurs as
a peak at the pA site (Rahl et al. 2010; Brookes et al. 2012;
Grosso et al. 2012; Hintermair et al. 2012). Global chro-
matin immunoprecipitation (ChIP) as well as analysis of
individual genes demonstrate that this correlates with
sites of Pol II pausing and is most frequently found
on short highly expressed genes with the canonical
AAUAAA motif (Glover-Cutter et al. 2008; Grosso et al.
2012). Pausing at pA sites is well characterized and
mediated by capture of the emergent AAUAAA hexamer
by CPSF bound to the body of Pol II (Nag et al. 2007). Pol II
pausing can also occur over sequences downstream from
the pA site, where it promotes transcriptional termina-
tion and 39 end formation (Eggermont and Proudfoot
1993; Gromak et al. 2006; West and Proudfoot 2009).
The processes involved in recognizing pA sites are
likely to be very relevant in the study of diseases such
as cancer, in which there are widespread changes in pA
signal usage (Mayr and Bartel 2009). When this is consid-
ered with its near-ubiquitous role in mRNA biogenesis,
it is important to understand it. A lot of research has
focused on elucidating the function of CTD modification
in RNA processing, but little is known about whether the
CTD code is influenced by pre-mRNA processing events
for their own benefit. We describe here reciprocal cou-
pling between 39 end processing and Ser2p. This mecha-
nism involves Pol II pausing that promotes Ser2p by Cdk12,
which serves to recruit CstF77 and is required for optimal
39 end processing.
Results
Ser2p levels are increased beyond the MYC
gene pA site
We chose the humanMYC gene as a model to analyze the
coupling between 39 end formation and transcription (Fig.
1A). It is highly expressed and was previously demon-
strated to be a robust model to analyze Pol II association
and processing factor recruitment (Glover-Cutter et al.
2008). ChIP was used to detect total Pol II (N20) or three
of its well-characterized derivatives phosphorylated on
CTD Ser5, Ser2, or Ser7 (Fig. 1B). It is important to note
that we used antibodies that are themost specific available
to these CTD states (Chapman et al. 2007; Hintermair
et al. 2012). All antibodies gave substantially more signal
than an IgG control (Supplemental Fig. 1). Pol II is most
concentrated at the promoter, with an additional pause at
the 39 end. Ser5p and Ser7p signals were also highest at the
beginning of the gene correlative with functions at the
promoter and in 59 capping (Komarnitsky et al. 2000;
Schroeder et al. 2000; Schwer and Shuman 2011). Ser2p
was low at the 59 end of the gene but showed a significant
peak beyond the pA signal. This peak of Ser2p at or shortly
after pA signals has been observed previously on theMYC
gene andmany other genes in yeast andmammals (Glover-
Cutter et al. 2008; Rahl et al. 2010; Preker et al. 2011;
Bataille et al. 2012; Brookes et al. 2012; Grosso et al. 2012;
Hintermair et al. 2012). While correlative with a function
in CPA, why and how Ser2p is enriched at this position is
not established in humans.
We also performed ChIP to monitor the recruitment
of the CPA factors CPSF30 and CstF77 to the MYC gene
(Fig. 1C). CPSF30 was detected at all positions, which is
consistent with the idea that CPSF may join Pol II at the
promoter (Dantonel et al. 1997; Nag et al. 2007; Glover-
Cutter et al. 2008). In contrast, CstF77 showed enrich-
ment beyond the pA signal, consistent with previous
reports that it is recruited at the end of the transcription
cycle (Glover-Cutter et al. 2008; Davidson and West
2013). This experiment suggests that some members of
the CPA machinery associate early with Pol II. However,
complete assembly of a functional CPA complex does not
occur until after the pA signal has been transcribed and is
coincident with the highest Ser2p signal.
The 39 peak of Ser2p could be explained by enhanced
phosphorylation at those positions. Alternatively, Ser2p
might already be present at upstream regions but in a
state that is masked from detection. These possibilities
are important to distinguish in order to properly interpret
the ChIP data. To do so, we performed native ChIP on the
MYC gene in the presence of high salt and SDS. We
predicted that this would unmask any Ser2p that is bound
by factors or obscured within CTD folding. Consistently,
CstF77 was undetectable under these conditions (Supple-
mental Fig. 2). However, Ser2p should remain detectable,
as Pol II is very tightly bound to DNA, aided by its so-
called clamp region (Gnatt et al. 2001). To test this, we
performed the experiment using the Ser2p antibody (Fig.
1D). Significantly, the Ser2p profile was very similar to
that obtained by standard ChIP. To confirm the peak at
the pA site, an extra primer pair was used spanning this
region (pA). This experiment strongly suggests that Ser2p
is increased beyond the pA site rather than being ob-
scured before it.
Cdk12 activity is important for Ser2p
and 39 end formation
In budding yeast, most Ser2p is achieved by Ctk1 func-
tion and is required for the recruitment of CPA factors to
genes (Ahn et al. 2004). Although CTD lacking Ser2
cannot efficiently recruit the CPA factor Pcf11 in humans
(Gu et al. 2012), the kinase involved has not been in-
vestigated. Recently, Cdk12 was shown to promote Ser2p
in metazoans and is the proposed ortholog of Ctk1
(Bartkowiak et al. 2010; Blazek et al. 2011). We used RNAi
to deplete Cdk12 from HeLa cells so that we could study
its function in Ser2p and 39 end formation.
Following confirmation of successful Cdk12 depletion
(Supplemental Fig. 3A), we performed ChIP on control
and Cdk12 knockdown cells using the N20 and Ser2p and
antibodies (Fig. 2A). Little difference in the Pol II profiles
was evident, but we observed a reduction in Ser2p signals
after the pA signal. This suggests that Cdk12 plays an
important role in establishing the Ser2p profile across
genes. Similarly, the CstF77 enrichment beyond the pA
Transcription-coupled 39 end formation
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site was reduced upon depletion of Cdk12 (Fig. 2B). The
recruitment of CPSF30, which has been proposed to
bind to the body of Pol II in addition to the CTD, was
unaffected by Cdk12 depletion as measured by ChIP
(Supplemental Fig. 3B). These experiments confirm that
Cdk12 phosphorylates Ser2p and suggest that this is
important to recruit some 39 end formation factors;
namely, CstF77. This mechanism is analogous to that
in budding yeast (Ahn et al. 2004). Finally, we analyzed
the recruitment of Cdk12 to the MYC gene by ChIP (Fig.
2C). Cdk12 was present over all regions, and the signal
was specific because it was reduced following treatment
with Cdk12 siRNA. Cdk12 is not enriched over the pA
site in comparisonwith upstream regions, suggesting that
the high Ser2p at this position depends on modulation of
Cdk12 activity.
We next wanted to establish whether impaired Ser2p
and CstF77 recruitment was important for overall 39 end
processing efficiency. We isolated total RNA from control
and Cdk12-depleted cells and reverse-transcribed it with
random hexamers. cDNA was then real-time PCR-am-
plified with primers spanning theMYC andGAPDH gene
pA site and downstream flanking regions such that only
unprocessed RNA was detected (Fig. 2D). More of these
unprocessed transcripts were detected following Cdk12
depletion, indicating that 39 end processing is more
efficient when coupled to Ser2p by Cdk12. To gain a greater
insight into this defect, we analyzed the rate of Myc pA site
processing (Fig. 2E). This was done by monitoring non-
pA-cleaved pre-mRNA following transcription inhibition
by Actinomycin D (Act D) using primers spanning the pA
cleavage site. In this experiment, cleavage at the pA site is
Figure 1. (A) Diagram of the human MYC gene
with exons (black boxes) and the pA site indicated.
Regions assayed by ChIP are underlined and la-
beled, and a scale marker is shown. (B) ChIP exper-
iment assaying the distribution of Pol II (N20), Ser5p,
Ser2p, and Ser7p across the MYC gene. For each
antibody, values are normalized to the maximum
value (see the Materials and Methods for details).
(NTS) A negative control region. (C) ChIP experi-
ment assaying the distribution of CPSF30 and
CstF77 across the MYC gene. For each antibody,
values are normalized to the maximum value. (NTS)
A negative control region. (D) Native ChIP analyzing
Ser2p across the MYC gene. Values are normalized
to the maximum value. (NTS) A negative control
region. All error bars represent standard deviation
from at least three biological replicates.
Davidson et al.
344 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on April 3, 2014 - Published by genesdev.cshlp.orgDownloaded from 
Figure 2. (A) ChIP experiment assaying the level and distribution of Pol II (N20) and Ser2p across the MYC gene in control or Cdk12-
depleted cells. Values are normalized to the maximal value obtained in control siRNA-treated cells. (B) ChIP experiment assaying the
level and distribution of CstF77 across the MYC gene in control or Cdk12-depleted cells. Values are normalized to the maximal value
obtained in control siRNA-treated cells. (C) ChIP experiment assaying the level and distribution of Cdk12 across the MYC gene in
control or Cdk12-depleted cells. IgG control values are also shown. Values are normalized to the maximal value obtained in control
siRNA-treated cells. (D) Real-time PCR analysis of RNA not yet pA-cleaved (UCPA) and readthrough (Flank) RNA from the MYC and
GAPDH genes in control and Cdk12-depleted samples. The diagram shows the final intron, pA site, and 39 flank. Quantitation shows
a fold change in Cdk12-depleted cells relative to control cells, normalized to terminal intron exon junction RNA. (*) P < 0.05. (E) Act D
time-course analysis of non-pA-cleaved (UCPA) RNA in control or Cdk12-depleted cells. RNA levels were normalized to those present
at time 0. (F) 4thio-UTP nuclear run-on (NRO) analysis of Myc transcriptional termination in control and Cdk12-depleted cells. The
graph shows the fold change in cells depleted of Cdk12 compared with control cells. Signals were normalized to those from the intron
2–exon 3 junction. (*) P < 0.05. All error bars represent standard deviation from at least three biological replicates.
Transcription-coupled 39 end formation
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predicted to cause a progressive loss of this product.
When compared with control cells, Cdk12 depletion
reduced the rate at which this species was lost, which is
consistent with slower pA cleavage. A modest reduction
in polyadenylatedMyc RNAwas also seen (Supplemental
Fig. 4A,B). Importantly, exosome depletion did not alter
the rate at which non-pA-cleaved Myc RNAwas depleted,
confirming that its loss is due to processing rather than
degradation of the precursor (Supplemental Fig. 4C).
Moreover, the rate of Myc splicing was unaffected by
Cdk12 depletion, arguing that 39 end formation is partic-
ularly sensitive to the presence of the protein (Supple-
mental Fig. 4E).
Defects in 39 end processing reduce the efficiency of
transcriptional termination (Whitelaw and Proudfoot 1986;
Dye and Proudfoot 2001; Gromak et al. 2006). To test
whether this was also a consequence of Cdk12 depletion,
we performed a nuclear run-on (NRO) analysis of Myc
transcripts (Fig. 2F). NRO detects RNA only from actively
transcribing Pol II, and signals observed are reflective of
the number of such polymerases at a given position on
the template. Nuclei from control and Cdk12-depleted
cells were incubated with 4-thio UTP to label nascent
transcripts, which were subsequently biotinylated and
purified before analysis by quantitative RT–PCR. We
analyzed RNA over the pA site (UCPA) as well as over
three downstream readthrough regions (F1, F2, and F2A).
Importantly, we observed significantly more readthrough
RNA over F2A in Cdk12-depleted cells as compared with
control cells, confirming that full levels of Cdk12 are
required for efficient Pol II termination in this case.
A functional pA site promotes high levels of Ser2p
Although our study focuses on a few model genes, a peak
of Ser2p at the pA site is a common and evolutionarily
conserved feature of protein-coding genes (Rahl et al.
2010; Bataille et al. 2012; Brookes et al. 2012; Grosso et al.
2012; Hintermair et al. 2012).Moreover, onCaenorhabditis
elegans operons, Ser2p peaks are found at each internal 39
end processing signal even though only a single pre-mRNA
precursor is synthesized (Garrido-Lecca and Blumenthal
2010). These data argue that an aspect of CPA is involved
in generating these high Ser2p signals to augment 39 end
formation. If this is the case, then mutation of a pA signal
should disrupt the accumulation of Ser2p at the 39 end of
a gene.
To test this hypothesis, we used two HEK293 cell lines
containing single-copy integrations of either the human
b-globin gene (bWT) or a version with a mutated pA site
(bpAm) (Davidson and West 2013). Expression of both
genes was driven by a tetracycline-inducible CMV pro-
moter (Fig. 3A). We performed ChIP on these b-globin
genes to detect Pol II or its Ser2p derivative (Fig. 3B).
Results were plotted to reflect the Ser2p levels normal-
ized to Pol II levels. In the case of bWT, the proportion of
Ser2p increased toward the 39 end of the b-globin gene,
similar to the MYC gene. In the case of bpAm, Ser2p
density was highest at the 59 end and had a generally
flatter profile. Why the signal for Ser2p is slightly elevated
at the 59 end for bpAm is not clear but could reflect the
disruption in processing. However, another ChIP experi-
ment on integrated b-globin genes with normal and
mutated pA sites gave a similar result, indicating that a
pA site mutation disrupts the Ser2p pattern (Mapendano
et al. 2010).
We next performed the reciprocal experiment by asking
whether de novo CPA would result in a corresponding
peak of Ser2p. To test this hypothesis, we took advantage
of the recently described function of U1 snRNA in in-
hibiting premature CPA (PCPA) (Kaida et al. 2010; Berg
et al. 2012). A prominent example of this occurs in the
NR3C1 pre-mRNA, which is subject to PCPA upon in-
hibition of U1 by an antisense morpholino (AMO). PCPA
is rapidly induced following U1 inhibition, and an abun-
dant product can be observed after 3 h (Davidson and
West 2013). This was confirmed by 39 RACE performed
on cells treated with control or U1 AMOs (Fig. 3C).
To see whether this PCPA event affected CTD phos-
phorylation, we performed ChIP analysis onNR3C1with
N20, Ser5p, Ser2p, and Ser7p antibodies in control and U1
AMO-treated cells (Fig. 3D). Primers were used to analyze
recruitment at positions between the promoter and 2 kb
beyond the PCPA site. The overall Pol II profile was similar
in both conditions over the regions assayed, but termina-
tion of transcription eventually occurred at downstream
positions (Supplemental Fig. 5). There was little change in
either Ser5p or Ser7p in U1 AMO samples compared with
control treatment, showing that PCPA does not influence
these modifications. Strikingly, the main difference be-
tween control and U1 AMO treatments was a dramatic
increase in the Ser2p signal beyond the PCPA site in U1
AMO samples compared with the control. Importantly,
a U2 AMO that inhibits splicing but does not promote
PCPA did not affect the level of Ser2p (Supplemental
Fig. 6). Thus, activation of a pA site induces high Ser2p,
providingmore support for a function of CPA in establish-
ing the pattern of Ser2p across genes and, in particular, in
promoting high levels of Ser2p near functional pA sites.
CPSF73 depletion reduces the level of Ser2p
on transcribed genes
To see whether trans-acting factors also mediate CPA-
dependent Ser2p, we used RNAi to deplete the pA endonu-
clease CPSF73 fromHeLa cells. After confirming successful
protein knockdown (Fig. 4A), we tested that the depletion
was sufficient to observe a 39 end processing defect. Total
RNA was isolated from control and CPSF73-depleted cells
and reverse-transcribed with random hexamers. Next,
primers spanning MYC or GAPDH gene pA sites were
used to perform real-time PCR and detect transcripts on
which CPA had not yet occurred (Fig. 4B). CPSF73 de-
pletion resulted in a threefold to fourfold increase in the
level of these species, establishing that protein levels
were sufficiently low to inhibit CPA. Consistently, Act D
time-course analysis revealed a substantial reduction in
the rate at which Myc transcripts were pA-cleaved (Fig.
4C), and fewer polyadenylated Myc transcripts were pro-
duced following CPSF73 depletion (Supplemental Fig. 7A,B).
Davidson et al.
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Next, we tested the effect that reduced CPA has on Pol
II loading and Ser2p. ChIP was performed on both con-
trol and CPSF73-depleted cells using the N20 and Ser2p
antibodies (Fig. 4D). CPSF73 RNAi caused little change in
Pol II occupancy, as determined by the N20 signal. How-
ever, its depletion resulted in a more dramatic effect on
Ser2p, which was reduced at all positions tested but in
particular over the region beyond the pA site. The same
Figure 3. (A) Diagram of bWT and bpAm genes integrated into HEK293 cells. The tetracycline-inducible CMV promoter (arrow), exons
(black boxes), and pA site are indicated. Regions assayed by ChIP are underlined. (B) ChIP across bWTand bpAm to detect the relative ratio
of Ser2p as compared with the Pol II (N20) signal. Note that the signal differential between Ex1 and 39B is significant (P < 0.05) for bWT but
not for bpAm. (C) 39 RACE detection of PCPA of NR3C1 pre-mRNA in total RNA from control and U1 AMO-treated cells. The top panel
shows the PCPA product, and the bottom panel shows product from the intronless TAF7 gene that acts as a loading control. The diagram
shows the NR3C1 gene and a zoomed region showing primer pairs to detect PCPA within intron 2. (D) ChIP across the 59 portion of the
NR3C1 gene to detect the distribution and level of Pol II, Ser5p, Ser7p, and Ser2p in control or U1 AMO-treated cells. The diagram shows
the 59 portion of the NR3C1 gene, and amplicons are indicated and underlined. For each antibody, values are normalized to the maximal
value obtained in control AMO-treated cells. All error bars represent standard deviation from at least three biological replicates.
Transcription-coupled 39 end formation
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was true for GAPDH and ACTB genes (Supplemental
Fig. 7C). Finally, Cdk12 protein levels were equivalent in
control and CPSF73-depleted cells, arguing that its indi-
rect depletion was not responsible (Supplemental Fig. 7D).
These data provide further evidence that efficient 39 end
formation is important to establish high levels of Ser2p by
implicating CPSF73 in the process.
Histone RNA processing defects are not associated
with changes in Ser2p level
CPSF73 catalysis is also a crucial part of histone pre-
mRNA processing, although these RNAs are not poly-
adenylated (Dominski et al. 2005; Kolev and Steitz 2005).
We were interested in whether there was also reciprocal
Figure 4. (A) Western blotting of protein extracts from cells treated with control or CPSF73 siRNAs. The top panel shows CPSF73
protein, and the bottom panel shows Tubulin loading control. (B) Real-time PCR analysis of RNA not yet pA-cleaved (UCPA) from the
MYC and GAPDH genes in control and CPSF73-depleted samples. Quantitation shows a fold change in CPSF73-depleted cells relative
to control cells normalized to the terminal intron–exon junction. (*) P < 0.05. (C) Act D time-course analysis of non-pA-cleaved (UCPA)
RNA in control or CPSF73-depleted cells. RNA levels were normalized to those present at time 0. (D) ChIP experiment assaying the
level and distribution of Pol II (N20) and Ser2p across the MYC gene in control or CPSF73-depleted cells. Values are normalized to the
maximal value obtained in control siRNA-treated cells. (E) Real-time PCR analysis of histone H1E RNA 39 end processing in control,
CPSF73-depleted, or Cdk12-depleted samples. The primer pairs used are indicated on the accompanying diagram. Quantitation shows
a fold change relative to control cells normalized to signal over the Histone gene body (59) (*) P < 0.05. (F) ChIP experiment assaying the
level and distribution of Pol II (N20) and Ser2p across the histone H1E gene in control or CPSF73-depleted cells. Values are normalized
to the maximal value obtained in control siRNA-treated cells. The diagram shows the positions of amplicons. All error bars represent
standard deviation from at least three biological replicates.
Davidson et al.
348 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on April 3, 2014 - Published by genesdev.cshlp.orgDownloaded from 
coupling between 39 end formation of histone transcripts
and Ser2p or the effect was pA site-specific. Using histone
H1E RNA as a model, we sought to confirm the role of
CPSF73 in histone RNA processing in vivo and test for
involvement of Cdk12. We performed quantitative RT–
PCR on total RNA from control, CPSF73-depleted, and
Cdk12-depleted cells using primers spanning the site of 39
end formation (Fig. 4E). We observed a substantial pro-
cessing defect in CPSF73-depleted cells, in line with its
anticipated role in histone RNA maturation. Impaired
processing was also observed in Cdk12-depleted samples,
indicating that Ser2p may also be important.
To investigate whether 39 end processing of histone
RNA by CPSF73 was involved in promoting Ser2p, we
performed ChIP on control and CPSF73-depleted cells
using Pol II and Ser2p antibodies (Fig. 4F). However, there
was little difference in the level or distribution of Pol II
or its Ser2p derivative in both conditions. Thus, 39 end
processing of histone RNA and CPSF73 catalysis per se
does not promote elevated Ser2p levels in a way that is
observable by ChIP. It should be noted that Ser2p levels
are much lower over Histone H1E as compared with
MYC, which may reflect the distinct mechanisms of 39
end formation (Supplemental Fig. 8).
CPA does not impact on Ser2p levels
We next wanted to determine the step in CPA that
promotes Ser2p. For this purpose, we subdivided CPA
into three stages: Pol II pausing and pA site recognition,
pA site cleavage, and polyadenylation. Polyadenylation
was tested first, as it distinguishes pA site processing
(which we found promotes Ser2p) from histone RNA
processing (which we found does not). Accordingly, we
compared Pol II and Ser2p ChIP signals on theMYC gene
in control cells or cells treated with cordycepin (CDY),
which inhibits polyadenylation (Fig. 5A). As previously
documented (Anamika et al. 2012), CDY caused a mild
reduction of Pol II signal at the promoter; however, the level
and distribution of Ser2p was not significantly changed.
Thus, polyadenylation does not positively impact on Ser2p.
We next askedwhether pA site cleavage promotes Ser2p.
This is not a trivial issue to address because separating
pA site recognition from cleavage is very difficult. How-
ever, we reasoned that if pA cleavage were a prerequisite
for high Ser2p levels, then non-pA-cleaved RNA would
only be found in association with Pol II that was not
heavily phosphorylated on Ser2. This would be in con-
trast to the situation by ChIP, where Ser2p peaks at the
pA site. To test this, we performed RNA immunoprecip-
itation (RNA-IP) of Myc transcripts with the Pol II and
Ser2p antibodies (Fig. 5B). We analyzed unspliced intron 1
(Ex1–In1), unspliced intron 2 (Ex2–In2), non-pA-cleaved
(UCPA), and 39 flanking region (F1) transcripts. Similar
amounts of each RNA were precipitated with the Pol II
antibody, but when the Ser2p antibody was used, UCPA
and F1 transcripts were immunoprecipitated more effi-
ciently than those upstream, consistent with the ChIP
data. If high Ser2p occurred only after pA site cleavage, it
might have been expected that no Ser2p peak would be
seen by RIP or that, if it was, UCPA transcripts would not
be associated with it. This result therefore suggests that
high Ser2p can occur on Pol II associated with transcripts
not yet pA-cleaved. In support of this, direct visualization
of transcription by other groups found that most Pol II
present beyond pA sites is associated with RNA that was
yet to be cleaved (Osheim et al. 1999, 2002).
As a further assessment of the role of pA site cleavage
in Ser2p, we used RNAi to deplete cells of CstF77 (Fig.
5C). This factor is important for pA site cleavage, but our
findings suggest that it is most efficiently recruited after
Ser2 becomes highly phosphorylated. We first tested
whether our depletion was sufficient to impair cleavage
of theMYC and GAPDH gene pA sites using RT–PCR on
RNA from control and CstF77-depleted cells (Fig. 5D).
Uncleaved pA sites from both genes accumulated twofold
to threefold following CstF77 depletion, confirming its
function in CPA. This was accompanied by a reduced rate
of Myc pA cleavage as measured by Act D time-course
analysis (Fig. 5E) and a reduction in the number of
polyadenylated Myc transcripts (Supplemental Fig. 9).
Finally, we performed ChIP under both conditions to
detect Pol II and Ser2p over the MYC gene (Fig. 5F). Im-
portantly, even though CstF77 depletion impaired pA site
cleavage, it did not affect Ser2p levels, indicating that the
two processes can be uncoupled. These data further argue
that Ser2p is promoted by a step prior to pA site cleavage.
Early events in 39 end formation promote Ser2p
We next considered the possibility that pausing over the
pA site might be responsible, since the 39 peak of Ser2p
that is observed genome-wide is coincident with a peak of
paused Pol II (Grosso et al. 2012). Furthermore, there is
little or no Pol II pausing on histone genes and no re-
ciprocal coupling of histone H1E RNA processing and
Ser2p, which is present at low levels (Fig. 4F; Supplemental
Fig. 8; Anamika et al. 2012).
It has been shown that binding of CPSF30 by non-
structural protein 1A (NS1A) from influenza virus abro-
gates AAUAAA-dependent Pol II pausing (Nag et al. 2007).
NS1A binds to CPSF30 and prevents the interaction of
CPSF complexes with pre-mRNA (Nemeroff et al. 1998).
We made two HEK293 cell lines containing a stably
integrated single copy of the wild-type NS1A gene or a
mutant version encoding NS1A that cannot bind CPSF30.
Transcription of both genes was driven by a tetracycline-
inducible promoter to allow rapid and coordinated ex-
pression (Supplemental Fig. 10A). This system is advan-
tageous over RNAi, since CPSF30 activity and 39 end
formation are more rapidly inhibited, and the mutant
that does not bind to CPSF30 is a robust control.
To test the system, total RNA was isolated from wild-
type and mutant NS1A cells induced with tetracycline.
Following random hexamer-primed reverse transcription,
uncleavedMyc and GAPDH pA sites were quantitated by
real-time PCR (Fig. 6A). Twofold to threefold more of
these species were present in cells expressing wild-type
NS1A when compared with those expressing mutant
NS1A, confirming that inhibition of CPSF30 impairs
CPA. Consistently, wild-type NS1A also impaired the
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recruitment of CPSF30 to the MYC gene (Supplemental
Fig. 10B). We next tested the effects of NS1A on the level
and distribution of Pol II and its Ser2p derivative (Fig. 6B).
Results for Pol II were similar in both cell lines, but Ser2p
levels were depleted at the 39 end of MYC in cells
expressing wild-type NS1A as compared with mutant
NS1A. This experiment provides further support for a role
of CPSF and Pol II pausing in promoting high levels of
Figure 5. (A) ChIP analysis of the level and distribution of Pol II and Ser2p in cells treated with DMSO or the polyadenylation inhibitor
CDY. Values are normalized to the maximal value obtained in DMSO-treated cells. (B) RNA-IP experiment using Pol II (N20) and Ser2p
antibodies detecting unspliced Myc intron 1 (Ex1–In1) and intron 2 (Ex2–In2) as well as non-pA-cleaved (UCPA) and flank (F1) RNA. For
each antibody, values are normalized to the maximal value obtained. (C) Western blot analysis of CstF77 (top panel) and PABPN1
(loading control; bottom panel) in cells treated with control and CstF77 siRNAs. (D) Real-time PCR analysis of RNA not yet pA-cleaved
(UCPA) from the MYC and GAPDH genes in control and CstF77-depleted samples. Quantitation shows a fold change in CstF77-
depleted cells relative to control cells, normalized to the terminal intron–exon junction. (*) P < 0.05. (E) Act D time-course analysis of
non-pA-cleaved (UCPA) RNA in control or CstF77-depleted cells. RNA levels are relative to those present at time 0. (F) ChIP
experiment assaying the level and distribution of Pol II (N20) and Ser2p across theMYC gene in control or CstF77-depleted cells. Values
are normalized to the maximal value obtained in control siRNA-treated cells. All error bars represent standard deviation from at least
three biological replicates.
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Ser2p at 39 ends of genes. CstF77 recruitment was also
reduced by expression of wild-type NS1A (Supplemental
Fig. 10B).
Pol II pausing is sufficient to promote Ser2p
The above data are consistent with a function for pA site
pausing in promoting Ser2p. To validate this model, we
sought to promote a single site-specific Pol II pause in
a region where Ser2p was normally low and test whether
it was increased as a consequence. We used the Strepto-
coccus pyogenes type II CRISPR system that has recently
proved useful for genome modification in human cells
(Cong et al. 2013; Mali et al. 2013). Briefly, a guide RNA
(gRNA) is used to target an endonuclease, Cas9, to a
chosen part of the genome. If a catalytically dead Cas9
(dCas9) is expressed, the complex remains bound to the
DNA, where it impedes Pol II progress (Gilbert et al. 2013;
Qi et al. 2013). To target this complex to the MYC gene,
we made a construct expressing a gRNA directed close to
the intron 1 exon 2 boundary of the MYC gene, where
Ser2p is lower than at the 39 end of the gene. To test
whether the MYC gRNA could restrict Pol II elongation,
cells were transfected with a dCas9 expression plasmid
and the MYC-specific or control gRNA constructs. Total
RNA was isolated and reverse-transcribed before being
real-time PCR-amplified with primers upstream of and
downstream from the gRNA-binding site (Fig. 6C). We
then calculated the ratio of downstream to upstream
RNA. When compared with cells expressing the control
gRNA, significantly less downstreamRNAwas recovered
in cells expressing the MYC gRNA. This indicates that
a proportion of Pol II is paused at the gRNA-binding site.
Finally, we performed ChIP on cells expressing dCas9
with either the control or MYC gRNA to detect Pol II or
Ser2p (Fig. 6D). When compared with the control gRNA,
Figure 6. (A) Real-time PCR analysis of Myc or GAPDH RNA that is not cleaved at the pA site (UCPA) in cells expressing wild-type or
mutant NS1A. Quantitation shows a fold change in wild-type NS1A cells relative to mutant NS1A cells normalized to the terminal
intron–exon junction. (*) P < 0.05. (B) ChIP experiment assaying the level and distribution of Pol II (N20) and Ser2p across theMYC gene
in wild-type (WT) or mutant (Mut) NS1A-expressing cells. Values are normalized to the maximal value obtained in mutant NS1A cells.
Primer pairs used are underlined on the accompanying diagram. (C) RT–PCR determination of Pol II pausing at the Myc gRNA. Levels
of RNA from upstream (US) of or downstream (DS) from the gRNA-binding site were compared and plotted. The graph shows the
DS:US ratio in cells expressing control or Myc-specific gRNA. The diagram shows primers and the position to which the Cas9:gRNA
complex is targeted (gray circle). (*) P < 0.05. (D) ChIP analysis of the level and distribution of Pol II (N20) and Ser2p across the MYC
gene in cells transfected with a dCas9 expression construct in addition to a plasmid expressing control or MYC-specific gRNA. Values
are normalized to the maximal value obtained in control gRNA transfected cells. All error bars represent standard deviation from at
least three biological replicates.
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the MYC gRNA caused a modest accumulation of Pol II
at the end of intron 1, where otherwise the pattern was
similar. This is consistent with the expected obstruction
to Pol II elongation provided by gRNA:dCas9. It should
be noted that not all MYC loci are likely to be bound
by gRNA:dCas9 due to incomplete targeting evident in
transfection-based genome-editing experiments (Wang
et al. 2013). Importantly, however, the MYC gRNA in-
duced a more substantial peak of Ser2p over this region.
These experiments strongly support the idea that Pol II
pausing can promote Ser2p.
Transcripts extending beyond the region of high
Ser2p are inefficiently cleaved at the pA site
We finally wanted to test whether the reciprocal coupling
that we describe is important for efficient CPA. Accord-
ingly, the rate of 39 end formation on transcripts from the
region of high Ser2p was compared with that of down-
stream RNAs produced by Pol II that escapes pausing. Pol
II over this downstream region (F3) displayed lower Ser2p
than that over upstream F1 and F2 regions (Fig. 7A). To
assay processing rates, we inhibited transcription using
Act D and isolated total RNA samples at 10-min intervals
over a 40-min period. Following reverse transcription with
random hexamers, real-time PCR was used to quantitate
RNA fromF1, F2, and F3 (Fig. 7B). Both F1 and F2 transcripts
were strongly depleted after only 10 min, which indicates
that pA cleavage takes place very quickly. In contrast, F3
RNA remained stable throughout the time course, indi-
cating that transcripts extending to this region were very
inefficiently processed compared with those upstream.
If the loss of F1 and F2 signal is a consequence of CPA, it
should be prevented when the process is impaired. To test
this, we repeated the Act D time course but analyzed the
decay of F1, F2, and F3 in cells expressing wild-type and
mutant NS1A protein (Fig. 7C). The decay in mutant
NS1A cells was rapid, as before; however, it was much
slower in cells expressing the wild-type protein, which
inhibits CPA. This result confirms that the low levels of
F1 and F2 transcripts observed following Act D treatment
were due to functional 39 end processing. There was little
difference between wild-type and mutant NS1A samples
assayed for F3, since transcripts extending to this region
are already poorly processed. In sum, these data strongly
suggest that the mechanism that we describe promotes
efficient CPA.
Discussion
We investigated how transcription, CTD modification,
and CPA are linked in human cells. We propose that a
reciprocal relationship between Ser2p and pausing during
CPA coordinates 39 end formation of pre-mRNAs and
transcription. We suggest that Pol II pausing, mediated by
the pA signal and CPSF, promotes high levels of Ser2p by
Cdk12. This augments the recruitment of CstF to form
a functional CPA complex to execute 39 end formation.
This mechanism is advantageous for 39 end formation, as
pA site cleavage is inefficient if Pol II reads through the
region of high Ser2p. Our model is presented in Figure 7D.
Our data indicate that the effect of CPA on Ser2p is
mediated by Pol II pausing, which is a well-described
consequence of pA signal transcription (Orozco et al. 2002;
Nag et al. 2007; Grosso et al. 2012). We argue this for
several reasons: First, the Ser2p signal increased over the
pA signal by ChIP and RNA-IP experiments, showing that
template-bound Pol II that is heavily phosphorylated on
Ser2 is associated with non-pA-cleaved RNA. Second, we
found that there is no effect of CPSF73 depletion on Ser2p
on the histone H1E gene even though processing is
impaired. This suggests that CPSF73 catalysis per se and
therefore pre-mRNA cleavage are not involved in Ser2p.
Consistently, it has been proposed that Pol II pausing is
transient or absent on histone genes (Anamika et al. 2012).
Third, we found that CstF77 depletion does not impact on
Ser2p even though pA site cleavage is impaired. Fourth,
site-specific Pol II pausing induced by dCas9 is associated
with a Ser2p peak even though no pA signal is present.
Finally, direct visualization of Pol II transcription by
electron microscopy indicates that Pol II that is associated
with pA-cleaved RNA is rarely seen either in Drosophila
or on human minigenes in Xenopus (Osheim et al. 1999,
2002). This being the case, the majority of the ChIP signal
beyond pA signals is likely to be contributed by Pol II that is
associated with unprocessed pA sites.
Our native ChIP experiment strongly suggests that
Ser2p is added beyond the pA site rather than being
present upstream but masked by bound factors. However,
it should be noted that CTD repeats with Tyr1p, Ser5p, or
Ser7p can be poorly detected by this Ser2p antibody in
vitro (Chapman et al. 2007; Hintermair et al. 2012).
Therefore, a Ser2p peak at the 39 end may result from
the loss of one or more of these inhibitory marks instead
of the gain of Ser2p. This would be reflected by a sharp pA
signal-dependent reduction in Tyr1p, Ser5p, or Ser7p,
but, to our knowledge, this has never been described in
humans. Finally, the H5 antibody is often used to detect
Ser2p but is less specific than the 3E10 antibody that we
used, as it reacts strongest with CTD phosphorylated on
Ser5 and Ser2 (Chapman et al. 2007). Even so, ChIP
sequencing with H5 or 3E10 generates very similar
average profiles, with peaks of signal at or beyond the
pA signal (Rahl et al. 2010; Brookes et al. 2012; Grosso
et al. 2012; Hintermair et al. 2012). As we propose, these
combined data support a straightforward model in which
Ser2p is increased after the pA site.
We showed that a transcriptional pause can act as a
molecular trigger for Ser2p, and a matter for future study
will be to understand how pausing leads to enhanced
Cdk12 activity. The ChIP experiments in Figure 2 dem-
onstrate that human Cdk12 is present across the MYC
gene. This is very similar to what was observed with
Drosophila Cdk12, which was detected broadly across
several tested genes (Bartkowiak et al. 2010). Pausing
might trigger Ser2p by localized recruitment of Cdk12 or
by promoting its activity. Our results favor the latter
because, although Cdk12 is present at the 39 end of the
MYC gene, there is not a striking peak. A further possibil-
ity is that Ser2p is repressed by a phosphatase that is
inactivated in a 39 end processing-dependent manner. We
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Figure 7. (A) Graph showing the relative ratio of Ser2p ChIP signal as compared with total Pol II (N20) over the F1, F2, and F3 regions.
Note that Ser2p/N20 is lowest for the F3 region (values normalized to those for the Ex2 amplicon). The diagram shows the position of
amplicons, and the region of high Ser2p is also indicated. (B) Act D time-course analysis of RNA from the F1, F2, or F3 regions of the
MYC gene 39 flank. For each product, values are plotted relative to those obtained at the 0 time point following normalization to U6
snRNA. (C) Act D time-course analysis of RNA from the F1, F2, and F3 regions of the MYC gene 39 flank in cells expressing wild-type
(wt) or mutant (mut) NS1A. For each product, values are plotted relative to those obtained at the 0 time point following normalization
to U6 snRNA. (D) Model: Upstream of the pA signal, Ser2p is present at lower levels, and CPSF accompanies Pol II. Transcription of the
pA site induces Pol II pausing (open red circle with slash) involving CPSF, and this triggers Ser2p by Cdk12. As a result, CstF77 is
recruited, and CPA takes place efficiently. Ser2p density is indicated by a color gradient of pink (lower) to red (higher) on the CTD. All
error bars represent standard deviation from at least three biological replicates.
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found this possibility unlikely given that most available
evidence does not support inhibition of Ser2p phospha-
tase activity at gene ends (Bataille et al. 2012; Fuda et al.
2012). Finally, our own preliminary analysis found that
Ser2p was not increased prematurely upon Fcp1 depletion
(data not shown).
Our observation of reciprocal coupling between CPA-
mediated Pol II pausing and CTD modification is an
important conceptual advance in understanding cotran-
scriptional pre-mRNA processing. We found that early
events in 39 end formation—specifically, Pol II pausing—
promote high levels of Ser2p. This modification is in turn
required for the efficient recruitment of a CPA complex
and subsequent 39 end formation. Thus, a pA signal is at
least partly responsible for generating the CTD state
necessary for its processing. We speculate that analogous
coupling might be used in other cases of cotranscriptional
RNAmaturation, in particular those requiring Ser2p. The
mechanism that we propose parallels another case of
reciprocal coupling between pre-mRNA maturation and
the chromatin template whereby Histone modification
and splicing influence one another (Luco et al. 2010; de
Almeida et al. 2011; Kim et al. 2011; Bieberstein et al.
2012).
Materials and methods
Primers
A list of primers, AMO sequences, and siRNA targets is provided
in Supplemental Table 1.
Plasmids
bWT and bpAm HEK293 cell lines were already described
(Davidson and West 2013). For gRNA expression, the gRNA
AAVS1-T1 plasmid (41817, Addgene) was modified by PCR to
include sequences complementary to MYC (see Supplemental
Table 1). dCas9 wasmade using the hCas9 D10A plasmid (41816,
Addgene) as a template for site-directed mutagenesis whereby
His841 was changed to Ala. To make the NS1A cell lines,
pcDNA-NS1 (a kind gift from Ervin Fodor) was amplified with
NS1F and NS1R. The product was then inserted into a vector
prepared by amplifying pcDNA5 FRT/TO, containing human
b-globin, with promR and bpAF primers. To make mutant NS1,
this plasmid was amplified with NS1mF and NS1mR primers.
Cell culture
Cells were grown in DMEM supplemented with 10% fetal calf
serum.ActDwas used at 10mg/mL. Electroporation ofmorpholinos
was performed on a confluent 10-cm-diameter dish of cells using
10 mMAMO in 400 mL of DMEM using a 4-mm gap cuvette (960
mF, 280 V in a Bio-Rad gene pulser). RNA was isolated 3 h after
electroporation. For transient transfection, 6 mg each of gRNA
and dCas9 constructs were transfected using JetPrime (Polyplus),
and experiments were performed 48 h later. For RNAi, 20%
confluent 60-mm dishes were transfected with 18 mL of 2 mM
siRNA and 5 mL of RNAiMAX (Life Technologies) and left for 72
h. The process was then repeated after replating of cells to 20%
confluence. Stable cell line generation was with the Flp-IN
system (Life Technologies) and is described elsewhere (Davidson
and West 2013).
Antibodies
Antibodies used were Pol II (N20:sc899, Santa Cruz Biotechnol-
ogy), Ser2p (3E10, ChromoTek), Ser5p (3E8, ChromoTek), Ser7p
(4E12, ChromoTek), CstF77 (C0249, Sigma), CPSF73 (C2747,
Sigma), CPSF30 (SAB4200170, Sigma; A301-584A, Bethyl Labo-
ratories), Tubulin (T6557, Sigma), Cdk12 for Western (NB100-
87011, Novus Biologics), PABPN1 (75855, Abcam), and Cdk12
for ChIP (57311, Abcam).
RNA analysis
Total RNA was isolated using Trizol (Life Technologies) and
DNase-treated with Turbo DNase (Life Technologies). For real-
time PCR analysis, 1 mg of RNA was reverse-transcribed using
Inprom II (Promega). Parallel reactions were performed in the
absence of reverse transcriptase. One-twentieth of the cDNA
mix was used for real-time PCR using 5–10 pmol of forward and
reverse primer and Brilliant III SYBR mix (Agilent Technologies)
in a Qiagen Rotorgene machine. Differences were calculated
using comparative quantitation.
ChIP
In a confluent 10-cm dish, HeLa or HEK293 cells were cross-
linked in 1% formaldehyde for 10 min at room temperature (4 3
60-mm dishes were used for RNAi experiments). Cross-links
were quenched in 125 mM glycine, and cells were rinsed in PBS
and then collected by centrifugation (500g for 5 min). Cells were
sonicated in 400 mL of RIPA buffer (150 mM NaCl, 1% NP40,
0.5% DOC, 0.1% SDS, 50 mM Tris-Cl at pH 8, 5 mM EDTA at
pH 8) for 30 sec on, 30 sec off for 12 min on high in a Bioruptor.
Chromatin was centrifuged at 13,000g for 10 min, and superna-
tants added to 20 mL of protein A/G Dynabeads (Invitrogen)
preincubated in 500 mL of RIPA buffer for 2 h with antibody
(generally 2–4 mg per ChIP). No antibody controls were per-
formed in parallel. Following overnight rotation at 4°C, the beads
were washed twice in RIPA buffer, four times in wash buffer (500
mM NaCl, 1% NP40, 1% DOC, 100 mM Tris.Cl at pH 8.5), and
twice in RIPA buffer. Immune complexes were eluted in 0.1 M
NaHCO3/1%SDS (15 min of rotation at room temperature).
Cross-links were reversed for 5 h at 65°C (250 mM NaCl, 1 mg
RNase A). DNA was phenol-chloroform-extracted and ethanol-
precipitated. Generally, 1/50th was used for each real-time PCR
reaction.
RNA-IP
For RNA-IP, the same protocol was used as for ChIP except
extracts were DNase-treated (30 min at room temperature) before
immunoprecipitation as well as after elution (1 h at 37°C). Im-
munoprecipitations were performed in the presence of RNase
inhibitor. Half of the elution was reverse-transcribed, and the
other half was used for a parallel minus reverse transcriptase
control.
Native high-salt ChIP
A 10-cm dish of HeLa cells was scraped in PBS and then lysed in
5 mL of HLB before underlayering with 1 mL of HLB + 10%
sucrose. Nuclei were pelleted by spinning at 500g for 5 min.
These were resuspended in 1mL ofMNase buffer, and chromatin
was digested for 10min at 37°Cwith 1U ofmicrococcal nuclease
(Sigma). Nuclei were then lysed in high-salt RIPA buffer (500
mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50 mM Tris-Cl at
pH 8, 5 mM EDTA at pH 8). Extracts were immunoprecipitated
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overnight in high-salt RIPA buffer in the presence of beads to
which antibodies had been coupled. The next day, these were
washed four times for 5 min in high-salt RIPA buffer and then
once in RIPA buffer. Elution and analysis were performed as for
standard ChIP.
ChIP quantitation
Our ChIP experiments often required data obtained from differ-
ent antibodies to be plotted on the same graph. Moreover, as
is common for ChIP, different batches of the same antibody
frequently varied in their effectiveness. Importantly, however,
the pattern of recruitment was always robust. To account for
this, values were plotted as relative percentage of input, where
we calculated the percentage of input for each experiment before
maximum immunoprecipitation as a relative percent input of 1.
Each plot displays the average and standard deviation of at least
three experiments quantitated in this way.
4-thio UTP NRO
A detailed protocol for 4-thio UTPNRO is described in Davidson
et al. ( 2012).
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